Safety and Efficacy of a Leadless Pacemaker: Results from the - - PowerPoint PPT Presentation

Safety and Efficacy of a Leadless Pacemaker: Results from the LEADLESS II clinical trial

Vivek Y. Reddy, MD, T. Jared Bunch, MD, Daniel J. Cantillon, MD, Rahul Doshi, MD, N.A. Mark Estes, MD, Derek V. Exner, MD, Paul Friedman, MD, Gery Tomassoni, MD, John Ip, MD, Kenneth Plunkitt, MD Icahn School of Medicine at Mount Sinai, New York, NY, Intermountain Medical Center Heart Institute, Salt Lake City, UT, Cleveland Clinic, Cleveland, OH, USC University Hospital, Los Angeles, CA, Tufts University, Boston, MA, Libin Cardiovascular Institute of Alberta, Calgary, Canada, Mayo Clinic, Rochester, MN, Central Baptist Hospital, Lexington, KY, Sparrow Research, Lansing, MI, Naples Community Hospital, Naples, FL.

• COI: St Jude Medical Inc – Grant support & Consultant
• I will be discussing the use of non-FDA approved devices

Reddy et al, N Eng J Med doi:10.1056/NEJMoa1507192

2015 Pacemaker State-of-the-Art

• Standard Pacemaker Technology:

– Highly mature & Overall reliable – Still includes generator, connector & lead

• Surgical Procedure:

– Surgical pocket + Transvenous leads

• Device issues – Pocket:

– Discomfort – Hematomas – Infections – Cosmetic concerns

• Leads:

– Mechanical failures – Infections; Extractions – Mobility restrictions – Challenge in compatibility with MRI

Hematoma Pocket Infection Infection  Erosion

Lead dislodgement Lead fracture

Complications of Standard Pacemakers

FOLLOWPACE Study [1517 Dutch Patients]

Udo et al, Heart Rhythm 9:728 –735 (2012)

12.4% at 2 months Substantial incidence of Complications

– Acute: 10-15% – Chronic: 9-10%

c c

Can we Avoid both Surgery & the Lead?

A Fully Self-Contained Pacemaker

Spickler et al, J.Electrocardiology, 3:325 (1970)

Proprietary and Confidential

6

• Percutaneous femoral vein delivery
• 18F introducer /steerable catheter
• <30 minute skin-to-skin procedure
• Self-contained device in ventricle
• No lead or surgical pocket
• Inherently MRI compatible
• Conventional Features
• Temperature-Based Rate Response
• >10-yr battery life
• Hysteresis
• Magnet Mode
• Flexible replacement options
• Catheter-based retrieval
• Place additional leadless pacemakers
• Revert to conventional pacing lead

Today’s Leadless Pacemaker System

The Nanostim Device

Leadless Pacemaker System

Implantation Procedure

Leadless Pacemaker Case

Device Implanted

First-in-Man Study of Leadless Pacing

LEADLESS: A 3-Center, 33-Patient Study

Reddy VY / Knops R / Neuzil P Circulation 129:1466 (2014 Ritter P, Eur Heart J doi:10.1093/eurheartj/ehv214

Leadless II Clinical Trial

Overview

• Prospective, multicenter, non-randomized, FDA IDE study
• Objective:

– To evaluate the clinical safety and efficacy of non-surgical implantation

• f the leadless cardiac pacemaker (LCP) system in patients who are

indicated for VVI(R) pacemaker.

• Primary Endpoints:

– Safety: Freedom from Serious Adverse Device Effects (SADEs) at 6 months – Efficacy: Acceptable pacing capture threshold (≤2.0 V at 0.4 msec) and a therapeutically acceptable sensing amplitude (R wave ≥5.0 mV, or a value equal to or greater than the value at implantation) through 6 mo.

• 56 Centers in the US, Canada and Australia

– 100 Operators – Of which, only one had prior experience with leadless pacing

Eligible subjects will meet all of the following:

• Subject must have an indication as per guidelines:

– Chronic AF with 2 or 3° AV or bifascicular BBB block, including slow ventricular rates associated with AF  55.9% – NSR with 2 or 3° AV or BBB block and a low level of physical activity or short expected lifespan  8.7% – Sinus bradycardia with infrequent pauses or unexplained syncope with EP findings  35.4%

• Subject ≥18 years of age; and
• Subject has life expectancy of at least one year; and
• Subject is not enrolled in another clinical investigation; and
• Subject is willing to comply with clinical investigation procedures and agrees to return

for all required follow-up visits, tests, and exams; and

• Subject has been informed of the nature of the study, agrees to its provisions and has

provided written informed consent, approved by the IRB; and

• Subject is not pregnant and does not plan to get pregnant during the course of the study

Leadless II Clinical Trial

Inclusion Criteria

Subjects will be excluded if they meet any of the following:

• Subject has pacemaker syndrome, has retrograde VA conduction or suffers a drop in

arterial blood pressure with the onset of ventricular pacing; or

• Subject is allergic or hypersensitive to <1 mg of dexamethasone sodium phosphate; or
• Subject has a mechanical tricuspid valve prosthesis; or
• Subject has a pre-existing pulmonary arterial (PA) hypertension (PA systolic pressure

exceeds 40 mmHg or RV systolic pressure (RVSP) as estimated by echo exceeds 40 mmHg), or significant physiologically-impairing lung disease (have severe pulmonary disease producing frequent hospitalizations for respiratory distress or requiring continuous home oxygen); or

• Subject has a pre-existing pacing or defibrillation leads; or
• Subject has current implantation of either conventional or subcutaneous implantable

cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT); or

• Subject has an implanted vena cava filter; or
• Subject has evidence of thrombosis in one of the veins used for access during the

procedure; or

• Subject had recent cardiovascular or peripheral vascular surgery within 30 days of

enrollment; or

• Subject has an implanted leadless cardiac pacemaker.

Leadless II Clinical Trial

Exclusion Criteria

• Pre-specified Primary Efficacy and Safety endpoints were analyzed in

the first 300 patients, followed for 6 months…occurred in June 2015 (Primary Cohort)

– Performance goal for the primary efficacy endpoint = 85% – Performance goal for the primary safety endpoint = 86%

• All analyses were conducted with the use of exact confidence intervals

for binomial proportions.

• The primary efficacy end point was assessed in the

– Intention-to-treat (ITT) population (All in whom implantation was attempted) – Patients with successful implant

• The primary safety end point was assessed in the ITT population
• Additional outcomes were assessed in all 526 patients who were

enrolled as of June 2015 (the Total Cohort)

• All adverse events were adjudicated by an independent CEC

Leadless II Clinical Trial

Methodology

Leadless II Clinical Trial

Patient Flow

Informed Consent Enrollment Implant Successful? No Yes Pre-Discharge 2-Week Post Implant Visit Follow Patient for 30 days, then withdraw 6-Week Post Implant Visit 3-Month Post Implant Visit 6-Month Post Implant Visit Every 6 months post implant until study completion

Reddy et al, N Eng J Med doi:10.1056/NEJMoa1507192

Leadless II Clinical Trial

Patient Demographics

Reddy et al, N Eng J Med doi:10.1056/NEJMoa1507192

Leadless II Clinical Trial

Patient Demographics

Reddy et al, N Eng J Med doi:10.1056/NEJMoa1507192

Leadless II Clinical Trial

Patient Demographics

Reddy et al, N Eng J Med doi:10.1056/NEJMoa1507192

Leadless II Clinical Trial

Procedural Characteristics

Successful Implantation 96.3% 95.8%

Reddy et al, N Eng J Med doi:10.1056/NEJMoa1507192

• Safety (Intent-to-Treat Analysis)

– 280 of the 300 patients achieved endpoint (93.3%; 95% CI = 89.9 to 95.9) – This exceeded the performance goal of 86% (P<0.001)

• Efficacy (Intent-to-Treat Analysis)

– 270 of the 300 patients achieved endpoint (90.0%; 95% CI = 86.0 to 93.2) – This exceeded the performance goal of 85% (P = 0.007)

• Efficacy (Successful implants)

– 289 patients with successful device implant – 270 of the 289 patients achieved endpoint (93.4%; 95% CI = 89.9 to 96.0) – This exceeded the performance goal of 85% (P <0.001)

 Thus, all endpoints were achieved

Leadless II Clinical Trial

Primary Endpoints

Reddy et al, N Eng J Med doi:10.1056/NEJMoa1507192

Leadless II Clinical Trial

Device-Related SAEs

4 4 1.3 6 6 1.1 2 2 0.6 3 3 0.6 3 3 0.9 10 10 1.9 4 4 1.3 8 8 1.5

* Includes: ischemic stroke, angina pectoris, pericarditis, acute confusion & expressive aphasia, dysarthria & lethargy post implant, contrast induced nephropathy, orthostatic hypotension with weakness, left leg weakness during implant, probable pulmonary embolism, ischemic stroke

* *

Reddy et al, N Eng J Med doi:10.1056/NEJMoa1507192

Freedom from SADEs

Primary Cohort (n=300)

Reddy et al, N Eng J Med doi:10.1056/NEJMoa1507192

Freedom from SADEs

Total Cohort (n=526)

Reddy et al, N Eng J Med doi:10.1056/NEJMoa1507192

Leadless II Clinical Trial

Device Electrical Measurements

Reddy et al, N Eng J Med doi:10.1056/NEJMoa1507192

Leadless II Clinical Trial

Battery Longevity: Projected vs “Observed”

Reddy et al, N Eng J Med doi:10.1056/NEJMoa1507192

Based on electrical parameters in the Primary Cohort, the battery longevity is estimated at 15.0 ± 6.7 yrs (95% CI, 14.2 to 15.8 yrs).

Percent Pacing (%) Battery Longevity (Years)*

500 Ohm Load 600 Ohm Load

100 8.8 9.8 75 10.6 11.7 50 13.3 14.5 25 17.9 18.9

* Assuming VVIR at 60 bpm, and output 2.5 V at 0.4 ms

• Retrieval of 7 implanted devices 

100% success without complications

• Time from implant: 160 ± 180 days (Range = 1 to 413 days)
• Reasons for retrieval
• Elevated Pacing Thresholds = 4 pts
• Worsening CHF = 2 pts
• Elective Explantation = 1 pt
• Retrieval is an important capability in the intermediate timeframe

Leadless II Clinical Trial

Retrieveability of Chronically-Implanted Devices

• The observed safety and efficacy of the Leadless Pacemaker

supports its use as an alternative to standard pacemakers in patients requiring single-chamber ventricular pacing.

• The device was successfully implanted in ~96% of patients.
• The trial met the pre-specified Safety and Efficacy endpoints
• Complication rate in line with that seen with conventional pacemakers
• Complication rate likely to improve with operator experience
• ( Rem: 99 of 100 operators had never implanted a leadless device )
• The device was shown to be retrievable in a group of patients

who needed a replacement

• The estimated device longevity (15.0 ± 6.7 yrs) is encouraging

Leadless II Clinical Trial

Conclusions

• An Observational study (not Randomized)
• Mean Follow-Up of only 6 months
• How to manage device after battery depletion?
• Possible to retrieve after ~1 year, but what about 5, 10, 15 yrs?
• Retrieval vs Abandonment
• Limited device diagnostics (eg, no electrogram data)
• Large venous sheath (18Fr)
• Now increasingly common used for cardiology procedures
• Low observed rate of hematomas
• Single‐chamber (RV) pacing only
• Device-to-device communication is in development …

Leadless II Clinical Trial

Limitations

Future of Leadless Pacemakers

Potentiated by Device-to-Device Communication

Dual-Chamber Pacemaker Single-Chamber Pacemaker Cardiac Resynchronization Leadless Pacemaker + Subcutaneous ICD Miller MA / Neuzil P / Dukkipati SR / Reddy VY J Am Coll Cardiol 66:1180 (2015) CRT-D